GLUCOCORTICOIDREZEPTORAGONISTEN

European patent · EP4314005 · In force

Register entry

Publication number
EP4314005
Application number
EP22715884
Kind
European patent with effect for Switzerland and Liechtenstein
Status
In force
Specification
Granted
Filed
Mar 22, 2022
Published
Feb 7, 2024
Granted
Feb 25, 2026
Protection ends at the latest
Mar 21, 2042
Next annual fee due
Mar 31, 2027
IPC classes
C07J 71/00 (2006.01)
A61P 17/00 (2006.01)
A61P 19/02 (2006.01)
Priority
US 202163164613 P 23.03.2021
US 202163260451 P 20.08.2021
PCT application
PCT/US2022/021299 22.03.2022
PCT publication
WO2022/204108 29.09.2022
Filing language
English
Source
Swissreg

History

What the Federal Institute of Intellectual Property published about this title, newest first.

  1. Apr 1, 2026

    Change

    Published in Swissreg on 01.04.2026

  2. Mar 13, 2026

    Agent entered

    Representative
    E. Blum & Co. AG, Hofwiesenstrasse 349, 8050 Zürich

    Published in Swissreg on 13.03.2026

  3. Feb 25, 2026

    Granted

    Specification status
    Non-published patent application → Granted patent
    Status of protective title
    Initiated → Active

    Published in Swissreg on 25.02.2026

Parties

Holder

Eli Lilly and Company

Lilly Corporate Center, Indianapolis, IN 46285, US

Agent

E. Blum & Co. AG

Hofwiesenstrasse 349, 8050 Zürich

Inventor

AHMED, Adel Ahmed Rashad

Indianapolis, Indiana 46206-6288, US

CLAYTON, Joshua Ryan

Indianapolis, Indiana 46206-6288, US

LOPEZ, Jose Eduardo

Indianapolis, Indiana 46206-6288, US

MCMILLEN, William Thomas

Indianapolis, Indiana 46206-6288, US

STITES, Ryan Edward

Indianapolis, Indiana 46206-6288, US

WILSON, Takako

Indianapolis, Indiana 46206-6288, US

WURST, Jacqueline Mary

Indianapolis, Indiana 46206-6288, US

The register names each party by name and address. A holder or agent is linked to an organization where exactly one entity of the commercial register bears its name; the street of a party not so recognised is not shown here.